Effect of Nutritional Supplements on Immune Function and Body Weight in Malnourished Adults

Lawrence J. Cheskin¹, Joseph Margolick², Scott Kahan¹, Andrea H. Mitola¹, Kavita H. Poddar¹, Tricia Nilles², Sanjivani Kolge¹, Frederick Menendez², Michelande Ridoré¹, Shing-Jung Wang³, Jacob Chou³ and Eve Carlson¹

¹Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society, ²Johns Hopkins Bloomberg School of Public Health, Department of Molecular Medicine and Immunology, ³Standard Foods/Quaker Oats, Taiwan. Email: lcheskin@jhsph.edu

Abstract: In the United States, approximately 5% of the population is malnourished or has low body weight, which can adversely affect immune function. Malnutrition is more prevalent in older adults and is often a result of energy imbalance from various causes. Dietary supplementation to promote positive energy balance can reverse malnutrition, but has not been assessed for its effect on immune parameters. This 8-week clinical feeding trial evaluated the effect of a commercially available, high-protein, high-energy formula on body weight and immune parameters in 30 adult volunteers with body-mass indices (BMI) <21 kg/m². After the intervention, participants gained a mean of 3.74 lbs and increased BMI by 0.58 kg/m². The intervention improved lean body mass and limited body fat accumulation. However, no clinically significant improvements in immune measures were observed. These results support the use of high-protein, high-energy supplements in the treatment of underweight/malnutrition. Further investigation utilizing feeding studies of longer duration, and/or studying severely malnourished individuals may be needed to detect an effect on immune parameters of weight gain promoted by nutritional supplements.

Keywords: malnutrition, nutritional supplements, immune function, body-mass index
Introduction
Malnutrition, often defined as a body mass index (BMI) of <18.5 kg/m², is a worldwide public health problem. Unlike nutrient losses due to chronic diseases, such as the Human Immunodeficiency Virus Wasting Syndrome,¹ most often low body weight is the result of a simple imbalance between energy intake from food and energy expended.² This phenomenon is seen with greater frequency among older adults, who may suffer from poor dentition, poor appetite, inattention to feeding, or poor mobility as a concomitant of declining cognitive function and/or depression, which may, in part, be attributed to physiologic changes with age.³,⁴

While the prevalence of underweight is much higher in Asia than most developed countries and Africa,⁵ in the United States, approximately 5% of the adult population has BMI below 21 kg/m². Most individuals who are malnourished or have low relative body weights (BMI < 21 kg/m²) can normalize weight by increasing energy intake through a variety of methods, including dietary supplements or appetite-stimulating medications.⁶ The most effective treatment provides a positive energy balance for both total calories and for protein.⁷ In the absence of adequate protein levels in the diet, weight gain will tend to increase fat stores rather than increase a combination of adipose and lean tissue.⁸,⁹ While malnutrition is known to have dramatic effects on immune function and susceptibility to infectious and other diseases, little is known regarding improvements in immune status upon weight gain or correction of malnutrition.

The current study aimed at investigating the effect supplementation with a high-energy and high-protein, commercially-available formula (Quaker Complete Nutrition, Standard Foods, Taiwan) in malnourished adults and those with a BMI below 21 kg/m². After 8 weeks of supplementation, we assessed weight and BMI changes, body composition, as well as immune markers and biochemical measures.

Methods
The study protocol was approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, and written informed consent was obtained from all eligible participants prior to participation.

Recruitment and eligibility
Potential participants were recruited from the Baltimore-Washington metropolitan area via newspaper and other advertisements and flyers which were placed around the Johns Hopkins medical campus. Participants were screened initially via telephone and subsequently at the clinic. Originally, participants were defined as eligible if they had a BMI < 18.5 kg/m². Because of the rarity of extremely low BMIs in our population in the absence of exclusionary factors, such as terminal illness, the BMI cut-point was subsequently increased to <21 kg/m². Participants were excluded if they were pregnant or nursing, had a food allergy, disliked the taste of vanilla, had a chronic disease such as HIV/AIDS or cancer that might account for their low BMI, or if they were unwilling to have their blood drawn or to gain weight. Participants were paid $10 for each visit, provided reimbursement for parking expenses, and received a $100 completion bonus.

Testing protocol
This was a pre-post supplementation clinical intervention study that included oral supplementation of the diet with 3–6 Quaker Complete Nutritional Shakes daily for 8 weeks. Data collected included height, body weight (BW), mid-arm circumference (MAC), mid-arm muscle circumference (MAMC), and triceps skin fold thickness measurements obtained by a trained technician at baseline (week 0), week 4, and follow-up (week 8) conducted according to ACSM guidelines for Exercise Testing and Prescription. Blood was collected at baseline (week 0) and follow up (week 8) for chemistries and immune function testing. Body composition was assessed via bioimpedence at week 0, week 4, and week 8. Participants were asked to return at weeks 1, 2, 4, 6 and 8 for weighing, completion of questionnaires regarding their diet, including a visual analog scale for assessing degree of hunger and satiety, and resupply with dietary supplements. Further dietary advice was also given; if participants wished/needed to continue efforts to gain weight, referral to a dietitian or medical clinic was made, if desired, in the final week (week 8) of the study.

Anthropometric and body composition measures
Height, body weight, MAC and MAMC measurements were obtained after overnight fasting with participants wearing lightweight clothing and no shoes. Weight
and height were measured using a balance beam scale with a stadiometer (Seca, Hanover, MD). MAC and MAMC were measured thrice to the nearest 0.5 cm and averaged. Total body composition was measured using bioimpedance (BIA) testing. BIA is a method of determining fat-free mass and percent body fat that entails measuring conductivity of a very small, painless electric current administered briefly via electrodes taped to the hands and feet.

Blood collection and analyses
Blood samples were collected after an overnight fast (3 tubes, <15 ml total) at baseline and at the end of the 8-week intervention. Blood was drawn from the antecubital vein into a Vacutainer tube. Serum was allowed to clot for 15 minutes and then centrifuged at 2000 g for 15 minutes at 4 °C. The serum was then pipetted into 2 mL polyethylene storage containers, topped with nitrogen gas, and quickly frozen on dry ice. Serum was stored at −70°C prior to analyses.

Immunological methods
Flow cytometry for the analysis of T-cell subsets and expression of activation markers was conducted according to standard methods. Within 24 hours of phlebotomy, fresh whole blood was incubated with appropriate directly conjugated monoclonal antibodies, as indicated in the Results section, with up to 4 antibodies conjugated to different fluorochromes used in the same staining tube. Red cells were then lysed with Becton-Dickinson lysing solution. Finally, the stained cells were fixed with 1% formaldehyde and analyzed on a Beckman Coulter XL flow cytometer capable of up to 4-color analysis.

Other immunological tests, including the complete blood count and differential and measurement of serum immunological markers were performed by commercial laboratories.

Intervention
Participants were instructed on how to use the Quaker dietary supplements (vanilla-flavored liquids of 250 kcal per 250 mL can), with the goal of incorporating 3–6 cans per day into their diet as snacks and/or meal supplements, thus potentially increasing energy intake by 750–1500 kcal/day. The number of cans recommended per day was based on subject eating habits (i.e. based on the number of meals and snacks that the subject consumed and the number of supplements of one-glass-size the subjects reported believing they could consume in addition to their usual diet).

Data analysis
Paired T-tests were used to analyze statistical significance. Significance was defined as $P$-value ≤ 0.05. Statistical trends were defined as a $P$-value ≤ 0.10. Exploratory and bivariate analyses were conducted using SPSS 17.0 statistical software (SPSS Inc., Chicago, Illinois). Descriptive statistics were analyzed using Stata (Version 10.0, Stata Corporation, College Station, TX).

Results
Subjects
Fifty five men and women aged 21 years or older were screened and 45 were found to be eligible to participate. Of those eligible, 55.6% were African American, 26.7% were Asian/Unknown and 17.8% were Caucasian. The age ranged from 21–77 yrs (mean = 38.9 ± 15) and mean weight was 118.9 ± 19.2 lbs. Mean BMI was 18.2 kg/m². Thirty participants (67%) completed the intervention. Table 1 describes study population demographics. Participants who dropped out of the study before 8 weeks were slightly younger on average compared to completers but had a similar mean baseline BMI.

Anthropometrics
Participants who completed the 8-week feeding intervention (n = 30) experienced a mean 3.74 lb (3.1%) increase in weight (from 119.91 lbs to 123.65 lbs) ($P < 0.01$). BMI increased by a mean of 0.58 kg/m² ± 0.12 ($P < 0.01$). Body fat percentage (%BF), measured by bioelectrical impedance, increased significantly from week 0 to week 8, by 1.04 ± 2.65% ($P = 0.039$). Both triceps and waist circumferences increased significantly as well, from 9.69 inches to 9.94 inches for triceps and by 1.0 inch for waist circumference ($P < 0.01$). (See Tables 2a and 2b). Table 3 details post-intervention changes in anthropometric and other selected variables.

Dietary measures
Completers had a mean total daily energy intake of 2923 kcal, consisting of intake from the nutritional supplement (980 kcal/day, range 625–1500 kcal),
and from other foods (1944 kcal/day, range 1190–2374 kcal).

With respect to the composition of the food energy consumed by participants, Table 4 shows the macronutrient breakdown of the foods consumed outside of the nutritional supplements provided. When added to the macronutrient profile of the nutritional supplement itself (21.6% fat, 64% carbohydrates, and 14.4% protein), the mean overall macronutrient composition of the total diet of participants was 28.48% fat, 52.79% carbohydrates, and 18.70% protein. Participants largely endorsed liking the taste of the product (see Table 5).

### Immune measures
The immunological studies that were performed were, for the most part, tests of nonspecific immunological parameters, rather than antigen-specific immune functions. Using multicolor flow cytometry, we analyzed the proportions of the major circulating lymphocytes subsets, expression of activation markers on T lymphocytes, and proportions of circulating

### Table 1. Demographic characteristics of study population.

| Characteristics | Total population (n = 45) | Completers (n = 30) | Drop-outs (n = 15) | Completers BMI between 13.1–18.5 |
|-----------------|---------------------------|---------------------|-------------------|----------------------------------|
| Gender:         |                           |                     |                   |                                  |
| M               | 22 (48.9)                 | 17 (56.7)           | 5 (33.3)          | 3 (30)                           |
| F               | 23 (51.1)                 | 13 (43.3)           | 10 (66.7)         | 7 (70)                           |
| Race:           |                           |                     |                   |                                  |
| White           | 8 (17.8)                  | 8 (26.6)            | 0                 | 1 (10)                           |
| Black           | 25 (55.6)                 | 17 (56.7)           | 8 (53.3)          | 7 (70)                           |
| Asian/Unknown   | 12 (26.7)                 | 5 (16.7)            | 7 (46.6)          | 2 (20)                           |
| Age (years)     | Range (21–77)             | Range (21–77)       | Range (22–51)     | Range (24–77)                    |
| Baseline BMI (kg/m²) | Range (13.1–20.8) | Range (13.1–20.8) | Range (14.7–20.6) | Range (13.4–18.3) |
| Baseline weight (lb) | Range (73.5–150.5) | Range (73.5–150.5) | Range (80.6–146) | Range 73.5–126.25 |

*Information in parentheses is percentage of observed population.

### Table 2a. Anthropometrics for completers only (week 0 vs. week 8, mean ± sd).

| Week | Weight (lb) | Height (in) | BMI (kg/m²) | Body fat% | Waist circumference (in) | Upper arm circumference (in) |
|------|-------------|-------------|-------------|-----------|--------------------------|-------------------------------|
|      | Wk 0        | Wk 8        | Wk 0        | Wk 8      | Wk 0         | Wk 8                         | Wk 0       | Wk 8       | Wk 0       | Wk 8       | Wk 0       | Wk 8       |
| Overall | 119.9       | 123.7       | 67.3        | 18.2      | 18.8         | 11.7                         | 12.5       | 27.8       | 28.6       | 9.7        | 9.9        |
|         | ±19.4       | ±20.6       | ±3.7        | ±2.2      | ±2.4         | ±5.7                         | ±5.9       | ±2.4       | ±2.5       | ±1.1       | ±1.3       |
| Males   | 131.8       | 136.3       | 70.0        | 18.5      | 19.1         | 8.4                          | 9.4        | 28.7       | 29.8       | 10.2       | 10.6       |
|         | ±14.0       | ±15.4       | ±2.4        | ±2.4      | ±2.7         | ±3.8                         | ±4.4       | ±1.4       | ±1.7       | ±0.9       | ±1.2       |
| Females | 104.3       | 107.1       | 63.9        | 17.9      | 18.4         | 16.0                         | 17.0       | 26.6       | 27.0       | 8.9        | 9.0        |
|         | ±13.4       | ±13.6       | ±1.9        | ±1.8      | ±1.9         | ±4.7                         | ±4.8       | ±2.9       | ±2.6       | ±0.9       | ±0.9       |
| Black   | 115.8       | 119.5       | 66.7        | 17.8      | 18.4         | 12.1                         | 12.8       | 27.5       | 28.3       | 9.6        | 9.8        |
|         | ±18.0       | ±18.3       | ±3.4        | ±2.4      | ±2.6         | ±6.1                         | ±6.8       | ±2.5       | ±2.4       | ±1.3       | ±1.4       |
| White   | 133.2       | 138.7       | 70.2        | 18.8      | 19.6         | 8.4                          | 10.0       | 28.8       | 30.0       | 9.9        | 10.2       |
|         | ±15.0       | ±18.3       | ±2.0        | ±2.2      | ±2.5         | ±3.8                         | ±4.2       | ±1.4       | ±1.8       | ±0.9       | ±1.1       |
dendritic cells at two time points, one before and one after the study intervention. Flow cytometry measurements were available for 29 of the 30 participants who completed the study.

Proportions of the major lymphocyte subsets (T cells, B cells, and natural killer (NK) cells) before and after the study intervention are shown in Table 6. Data are expressed as the percent of lymphocytes belonging to the indicated subset. These three subsets together represent nearly 100% of circulating lymphocytes. None of the subjects studied had overtly abnormal percentages of these subsets. As shown in Table 6, there were no significant changes in the two major subsets of T cells (CD4+ or helper T cells, and CD8+ or suppressor-cytotoxic T cells). (Statistical significance was assessed by the paired t-test.)

Table 7 shows the expression of several activation markers by circulating T cells (CD3+ lymphocytes). The activation markers assessed were CD69 (an early marker of activation), CD38 (a marker of global cell activation and maturity), HLA-DR (a Class II major histocompatibility protein which is expressed by activated T cells), and CD25 (the α-chain of the high affinity interleukin 2 receptor, expressed on activated T cells and regulatory T cells). Data are expressed as the percent of T cells expressing the indicated phenotype (one or more immunological markers as indicated in the table row headings). Again, there were no major differences between the pre- and post-intervention time points. Only one phenotype (CD38+ CD25−) changed significantly, and that difference was of borderline significance ($P = 0.05$). The total percentage of CD38+ cells was not significantly affected by the treatment. This analysis included 25 subjects, rather than 29, because there was a delay in validating the panel

| Variable                | Mean change | Unit | $P$ value |
|-------------------------|-------------|------|-----------|
| Weight                  | +3.74 (3.1%)| lbs  | $P < 0.01$|
| BMI                     | +0.58       | kg/m²| $P < 0.01$|
| Triceps circumference   | +0.25       | in   | $P < 0.01$|
| Waist circumference     | +1.00       | cm   | $P < 0.01$|
| Body fat                | +1.04       | %    | $P = 0.039$|
| Absolute basophils      | +9.28       | mg/dL| $P = 0.037$|
| Glucose*                | +11.84      | mg/dL| $P = 0.027$|

*Some glucose samples were hemolysed.
of monoclonal antibodies used to detect the activation markers.

Finally, we analyzed the proportion of circulating lymphocytes that expressed markers characteristic of dendritic cells. These are potent antigen-presenting cells that circulate at very low proportions in the peripheral blood. The dendritic cells were identified by expression of either CD123 or CD11c, along with HLA-DR and a lack of surface markers for T, B, or NK cells. As shown in Table 8, there was a small increase the CD11c+ dendritic cell subset that was of borderline statistical significance ($P < 0.05$). This should be considered a very preliminary finding in view of the small magnitude of the effect and the overall number of statistical comparisons that were performed.

Table 9 details laboratory blood and serum test results, and is notable for the absence of adverse effects.

### Discussion and Conclusions

We originally hypothesized that a supplement-enriched diet, in the form of the Quaker Complete Nutrition Foods, would result in improvements in body weight, BMI, and body composition as assessed by bioimpedance. The results suggest that the product did indeed have a significant impact on all these measures over the course of a relatively brief, 8-week intervention period, likely as a result of increasing both total daily energy intake, and amount of protein consumed, both derived from the nutritional supplements themselves, and from an increased consumption of other foods, including those containing a greater amount of protein. 2005 dietary guidelines for Americans from the United States Department of Health and Human Services and the United States Department of Agriculture report that the total daily energy requirements of an average American adult range from 1625 to 3720 kcal, inclusive of height ranges of 59 inches to 71 inches and BMI ranges of 18.5 km/m² to 24.99 kcal/m². According to the Food and Agriculture Organization/World Health Organization, between the ages of 20–30 years, an average woman or man with a moderately active lifestyle requires 2410 kcal and 3074 kcal/day, respectively. These figures place our participants completing the study squarely within typical intake levels, in contrast to their pre-study baseline intakes. The mean overall macronutrient composition of the total diet of participants was 28.5% fat, 52.8% carbohydrate,
and 18.7% protein. This is also consistent with USDA Food Guide Pyramid recommendations of 20%–35% fat, 45%–65% carbohydrate, and 10%–15% protein, and is sufficiently high in protein to facilitate increases in lean mass accompanying the weight gain experienced. In fact, participants appeared to be more likely to increase their intake of protein from sources even outside of the nutritional supplements provided following initiation of the study.

We also hypothesized that the supplement-enriched diet would result in improvements in body protein stores/albumin, other biochemical parameters, and improvements in immunological function and other immunologic parameters. While biochemical measures other than fasting serum glucose showed no significant change following the intervention, there were no adverse biochemical or blood changes. This suggests, consistent with the anthropometric and bioimpedance results, that the 8-week nutritional supplementation was effective in increasing lean body mass while limiting body fat accumulation.

A very recent study conducted in elderly patients with reduced body lean mass showed that dietary supplements with amino acids do increase body lean mass

| T cell phenotype | Baseline | Post-intervention | P value** | Change within individual |
|-----------------|----------|------------------|-----------|--------------------------|
|                 | Mean     | Std dev          | Mean      | Std dev                  | Mean     | Std dev |
| CD38+           | 43.3*    | 15.7             | 43.9      | 15.0                     | 0.72     | 1.1      | 8.2     |
| CD25+           | 26.9     | 13.8             | 24.8      | 8.6                      | 0.40     | -2.3     | 12.6    |
| HLADR+          | 2.6      | 1.6              | 2.6       | 1.5                      | 0.36     | 0.1      | 0.9     |
| CD69+           | 3.7      | 4.6              | 4.1       | 3.6                      | 0.55     | 0.4      | 3.4     |
| CD38+ CD25−     | 35.7     | 14.3             | 38.6      | 13.9                     | 0.05     | 2.9      | 7.2     |
| CD38+ CD25+     | 7.4      | 5.4              | 6.8       | 3.9                      | 0.61     | -0.6     | 6.1     |
| CD38− CD25+     | 19.5     | 11.1             | 18.6      | 8.2                      | 0.54     | -0.9     | 7.2     |
| CD38− HLA−DR−   | 41.9     | 15.6             | 42.5      | 15.0                     | 0.72     | 0.6      | 8.2     |
| CD38+ HLA−DR+   | 1.4      | 1.0              | 1.4       | 0.9                      | 0.84     | 0.0      | 0.6     |
| CD38− HLA−DR+   | 1.2      | 0.8              | 1.2       | 0.8                      | 0.59     | 0.1      | 0.6     |
| CD25+ HLA−DR−   | 26.1     | 13.4             | 24.2      | 8.6                      | 0.43     | -2.1     | 12.0    |
| CD25+ HLA−DR+   | 0.8      | 0.6              | 0.6       | 0.3                      | 0.13     | -0.2     | 0.5     |
| CD25− HLA−DR+   | 1.9      | 1.2              | 1.9       | 1.3                      | 0.71     | 0.1      | 0.9     |
| CD69+ CD25−     | 2.5      | 2.0              | 3.1       | 2.4                      | 0.26     | 0.6      | 2.5     |
| CD69+ CD25+     | 1.3      | 3.0              | 1.2       | 1.9                      | 0.57     | -0.2     | 1.4     |
| CD69− CD25+     | 26.6     | 14.6             | 25.0      | 8.1                      | 0.55     | -1.6     | 13.1    |
| CD69− HLA−DR−   | 3.6      | 4.3              | 3.6       | 3.2                      | 0.99     | 0.0      | 3.4     |
| CD69+ HLA−DR+   | 0.1      | 0.1              | 0.2       | 0.3                      | 0.32     | 0.0      | 0.2     |
| CD69− HLA−DR+   | 2.3      | 1.2              | 2.3       | 1.1                      | 0.95     | 0.0      | 0.9     |

*Data shown are percentages of total (CD3+) T cells as identified using flow cytometry on 25 donors.
**Determined by paired t-test.

Table 8. Percentages of dendritic cells among total leukocytes before and after study intervention, and within-person changes.

| Dendritic marker | Baseline | Post-intervention | P value** | Change within individual |
|------------------|----------|------------------|-----------|--------------------------|
|                  | Mean     | Std dev          | Mean      | Std dev                  | Mean     | Std dev |
| CD123            | 0.3*     | 0.2              | 0.3       | 0.2                      | 0.70     | 0.01     | 0.12    |
| CD11c            | 0.8      | 2.1              | 1.1       | 2.7                      | 0.05     | 0.22     | 0.60    |

*Data shown are percentages of total (CD3+) T cells as identified using flow cytometry (n = 29)
**Determined by paired t-test
over an intervention period of 8–18 months.\textsuperscript{12} We further find that lean body mass can increase over a period as short as 8 weeks in underweight, younger subjects when they are provided with nutritional supplements that contain relatively high levels of protein and are viewed as tasty by participants.

Of note, percent body-fat (\% BF), measured by bioimpedance, increased by 1.04 ± 2.65\% (P = 0.039). This increase in body fat, being only about one-third as large as the increase in body weight seen (3.1\%) suggests that the weight gain consisted largely of an increase in lean body mass. In addition, as judged by

### Table 9. Blood and serum laboratory measures: pre vs. post-intervention (mean ± sd) results from all completers/participants with valid lab results, n = 30.

| Lab test                  | Pre-intervention (completers and drop-outs)* | Post intervention (completers only) | Reference range and units |
|---------------------------|---------------------------------------------|------------------------------------|---------------------------|
| White blood cell count    | 5.8 ± 2.3 (3–12)                            | 6.1 ± 2.4 (2–13)                  | 3.8–10.8 Thousand/MCL     |
| Hemoglobin                | 13.3 ± 1.5 (9–17)                           | 13.5 ± 1.6 (8–16)                 | 3.8–5.10 Million/MCL      |
| Hematocrit                | 39.4 ± 4.7 (28–50)                          | 39.6± 4.7 (24–47)                 | 11.7–15.5 G/DL            |
| MCV                       | 90.7 ± 7.7 (70–107)                         | 91.0 ± 7.0 (64–107)               | 35.0–45.0%                |
| Platelet Count            | 239.0 ± 59.3 (98–380)                       | 237.0 ± 57.6 (103–549)            | 80–100 FL                 |
| Absolute Neutrophils      | 3264.8 ± 1708.9 (957–10529)                | 3507.1 ± 1300.3 (1275–6371)       | 27–33 PG                  |
| Percent Neutrophils       | 56.6 ± 11.7 (26–86)                         | 59.3 ± 8.6 (41–76)                | %                        |
| Absolute Lymphocytes      | 1647.6 ± 632.4 (572–3072)                  | 1667.3 ± 697.8 (825–3784)         | 850–3900 Cells/MCL        |
| Percent Lymphocytes       | 30.6 ± 9.3 (8–53)                           | 28.6 ± 7.1 (8–40)                 | %                        |
| Absolute Monocytes        | 4267.7 ± 157.8 (228–875)                   | 424.4 ± 145.9 (198–690)           | 200–950 Cells/MCL         |
| Percent Monocytes         | 8.0 ± 2.7 (3–14)                            | 7.8 ± 2.6 (4–12)                  | %                        |
| Absolute Eosinophils      | 284.1 ± 1071.2 (0–6954)                    | 342.2 ± 1173.8 (0–6072)           | 15–550 Cells/MCL          |
| Absolute Basophils        | 24.8 ± 18.9 (0–58)                          | 34.1 ± 23.2 (0–115)               | 0–200 Cells/MCL           |
| IgA Serum                 | 251.7 ± 109.8 (64–491)                     | 226.9 ± 100.8 (62–436)            | 81–463 mg/dL              |
| IgG Serum                 | 1403.2 ± 445.7 (747–2645)                  | 1384.9 ± 429.8 (776–2523)         | 694–1618 mg/dL            |
| IgM Serum                 | 151.7 ± 120.9 (31–693)                     | 154.7 ± 136.8 (29–677)            | 48–271 mg/dL              |
| Tetanus Antitoxoid AB     | 3.8 ± 2.4 (0–7)                             | 3.6 ± 2.3 (0–7)                   | >0.15 IU/mL               |
| Protein, total            | 7.6 ± 0.6 (6–9)                             | 7.5 ± 0.6 (6–8)                   | 6.2–8.3 G/DL              |
| Albumin                   | 4.3 ± 0.5 (4–5)                             | 4.4 ± 0.5 (4–5)                   | 3.6–5.1 G/DL              |
| Globulin Calculated       | 3.1 ± 0.6 (2–4)                             | 3.1 ± 0.7 (1–4)                   | 2.2–3.9 G/DL              |
| A/G Ratio                 | 1.6 ± 0.5 (1–2)                             | 1.5 ± 0.5 (1–2)                   | 1.0–2.1 (Ratio)           |
| Bilirubin Total           | 0.7 ± 0.7 (0–3)                             | 0.6 ± 0.6 (0–2)                   | 0.2–1.2 MG/DL             |
| Bilirubin Direct          | 0 ± 0 (0)                                   | 0.03 ± 0.2 (0–1)                  | 0.0–0.2 MG/DL             |
| Bilirubin Indirect        | 0.5 ± 0.7 (0–3)                             | 1.0 ± 3.9 (0–20)                  | 0.2–1.2 MG/DL             |
| AST                       | 24.3 ± 11.9 (12–67)                         | 32.5 ± 31.2 (13–167)              | 10–30 U/L                 |
| ALT                       | 18.6 ± 10.6 (6–59)                          | 28.4 ± 33.8                       | 6–40 U/L                  |
| LDH                       | 207.0 ± 97.0 (119–758)                      | 219.9 ± 191.4 (107–1138)          | 100–200 U/L               |
| Alkaline phosphase        | 71.2 ± 22.8 (40–129)                        | 69.3 ± 23.6 (22–137)              | 33–115 U/L                |
| GGT                       | 55.3 ± 151.4 (12–965)                       | 30.5 ± 31.0 (11–174)              | 3–50 U/L                  |
| Glucose\textsuperscript{2} | 49.8 ± 16.5 (27–92)                         | 61.6 ± 21.0 (15–92)               | 65–99 MG/DL               |
| Urea Nitrogen             | 13.7 ± 5.1 (8–28)                           | 13.5 ± 5.4 (7–30)                 | 7–25 MG/DL                |
| Creatinine                | 1 ± 0 ()                                    | 1 ± 0 ()                          | 0.5–1.2 MG/DL             |
| BUN/Creatinine            | 16.7 ± 5.8 (8–34)                           | 15.9 ± 4.9 (10–28)                | 6–22 (Ratio)              |
| Calcium                   | 9.5 ± 0.6 (8–10)                            | 9.6 ± 0.5 (9–10)                  | 8.6–10.4 MG/DL            |
| Total Cholesterol         | 169.2 ± 33.6 (118–265)                      | 157.3 ± 42.0 (92–266)             | 125–200 MG/DL             |
| Triglycerides             | 70.4 ± 30.5 (29–166)                        | 62.75 ± 22.9 (24–131)             | <150 MG/DL                |
| HDL Cholesterol           | 66.0 ± 23.4 (31–137)                        | 66.4 ± 23.4 (35–145)              | <46 MG/DL                 |
| LDL Cholesterol           | 89.1 ± 25.7 (52–176)                        | 77.7 ± 30.7 (36–189)              | 0–100 MG/DL               |
| Total/HDL Ratio           | 2.56 ± 1.0 (1.6–6.5)                        | 2.5 ± 0.6 (2–4)                   | 0.0–5.0 (Ratio)           |

\*Information in parentheses represents range of values in study population (min-max).
\textsuperscript{2}Some post-intervention glucose samples were hemolysed and values may not be reliable.
the lack of significant change in BUN/creatinine ratio, there is no evidence of a change in state of hydration accounting for the change in body weight.

None of the participants experienced significant adverse effects related to consuming the nutritional supplement. Most were able to fully complete the intervention and on average found the taste of the product to be satisfactory. Participants were discharged early from the study if they missed more than 2 consecutive visit appointments and could not be reached by phone to set up follow-up visits. While we do not have a breakdown of reasons for dropout (all subjects dropped were due to missed appointments), many dropouts found it difficult to continue the study if they did not have a ready means of transportation or did not wish to have repeat blood draws.

As a result of the intervention, there were no significant changes in CBC values and/or biochemistry values, except for absolute basophil counts, which saw a modest increase of 9.28 cells/mcl ($P = .037$), which is still in the normal range, and blood glucose, which increased 11.84 mg/dL ($P = .027$). Blood glucose was still, on average, in the low-normal range, so this increase is not likely to be of adverse clinical significance and may be a favorable change for these undernourished individuals. Also, some glucose samples were hemolysed, reducing reliability.

We also tested the hypothesis that the immune system would be affected by the nutritional supplement intervention. Tests of general immune function were performed on samples from before and after the intervention. These tests measured serological and cellular immune parameters reflecting overall, rather than antigen-specific status of the immune system. The data indicate that there were very few immune-related changes associated with the intervention. We studied proportions of dendritic cells in the peripheral blood because nutritional interventions have been reported to affect these, but no convincing effect of the intervention in this study was found. There was a slight increase in the number of circulating basophils, the proportion of circulating T-cells expressing one activation marker phenotype out of 19 measured, and one subset of circulating dendritic out of two measured. All of these increases were small and their statistical significance was borderline. If one takes into account the fact that multiple statistical comparisons were made in this study, these changes must be considered preliminary findings that will require replication.

Overall, there were no significant changes in immune function and/or T-cells, nor in dendritic and activation cells following this 8-week intervention. Thus, the data do not support any important changes in numbers or proportions of circulating granulocytes or lymphocytes, or in the activation level of the immune system.

It remains possible that functional assays of immune functions, such as lymphoproliferation assay, detection of secreted cytokines by ELISA, or enumerating individual cytokine-producing T-cells by ELISPOT assay, detection of intracellular cytokines by multi-parameter flow cytometry, measurement of cytokine mRNA levels by real time quantitative RT-PCR, quantifying CTL precursors by LDA, which are more sensitive for assessment of these functions, might have detected effects of the study intervention. However, these tests were beyond the scope of the present study.

Other possible factors that might have contributed to the lack of immunological effects in this study are the relatively short intervention period and the fact that the subjects studied did not show evidence of immunological abnormalities at baseline. Relevant to this conclusion is that a randomized, controlled study involving 96 elderly men and women (mean age 74.5) showed that at the end of 12 months, several immunological responses were statistically significantly improved in the nutritionally-supplemented group. These positive effects included increases in number of T-cells and NK cells, IL-2 production, IL-2 receptor release, NK cell activity, and antibody response to influenza vaccine. This study also showed that improvement in immunological responses was greater among the subjects who were nutrient deficient at baseline and had shown evidence of correction following the use of nutritional supplementation over 12 months.

This suggests that, while the current study only showed immune effects that were borderline in significance, a longer-term study and/or one which studies older, more severely nutritionally compromised individuals would be more likely to show a benefit of this type of supplementation on multiple immune markers. On the other hand, the lack of effect of the intervention is reassuring in that there was no apparent adverse effect of the intervention on the
parameters measured, including T-cell subsets and immune activation markers. Another limitation of the study is that it utilizes a pre-post design, rather than a parallel control group. While a control group is preferable, we did not feel it was appropriate to offer placebo treatment to undernourished individuals seeking treatment. Moreover, we feel the practical question of whether nutritional supplements do help reverse under/malnutrition can be addressed without a control group.

Lastly, we hypothesized that the diet would be of favorable palatability, and this was confirmed by the overall high taste ratings from participants in this study. This suggests that Quaker Complete Nutrition Foods may be well-tolerated and of benefit for malnourished individuals interested in using nutrition supplements long-term. While the significance of some findings of this study was constrained due to the relatively small sample size, there are a number of positive outcomes and study strengths. For example, the range of body sizes and the distribution of race, gender, and age was broad, providing a suggestion that the results may generalize across demographic groups.

Given the aforementioned results, we conclude that the findings of this study provide strong support for the utility of the product tested for the short-term treatment of underweight and malnutrition in a broadly-based, US adult population. Future work should explore the outcomes of supplement-enriched diets for long-term use. If such a study is undertaken, we suggest that, although no consistent general immune effects were found in the present short-term study, any future long-term study should look at additional functional parameters of immune function, such as response to immunologic challenge.

Disclosures
This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors and peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

References
1. Bartlett JG, Gallant JE. Medical Management of HIV Infection. Baltimore: Johns Hopkins Medicine Health Publishing Business Group, 2007.
2. Chow CC, Hall KD. The dynamics of human body weight change. PLoS Comput Biol. 2008 Mar 28;4(3). PubMed PMID: e1000045.
3. Drewnowski A, Shultz JM. Impact of aging on eating behaviors, food choices, nutrition, and health status. J Nutr Health Aging. 2001;5(2):75–9.
4. Morley JE. Nutrition and cognition in older persons. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;6:121–3. discussion 130–4.
5. De Onis M, Monteiro C, Akre J, Clugston G. The worldwide magnitude of protein-energy malnutrition: an overview from the WHO Global Database on Child Growth. Bull World Health Organ. 1993;71(6):703–12.
6. Silver HJ. Oral strategies to supplement older adults’ dietary intakes: comparing the evidence. Nutr Rev. 2009 Jan;67(1):21–31.
7. Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev. 2009 Apr 15;(2).
8. Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):86–90.
9. Shah M, Garg A. High-fat and high-carbohydrate diets and energy balance. Diabetes Care. 1996 Oct;19(10):1142–52.
10. U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans, 2005. 6th Edition, Washington, DC: U.S. Government Printing Office, January 2005.
Nutrition and Metabolic Insights 2010:3

11. World Health Organization, United Nations University and Food and Agriculture Organization of the United Nations. Human Energy Requirements: Report of a Joint FAO/WHO/UNU Expert Consultation. 2001 Oct;(1):17–24.

12. Solerte SB, Fioravanti M, Locatelli E, et al. Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus. Am J Cardiol. 2008 Jun 2;101(11 A):82E–8E.

13. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for Monitoring Cellular Immune Responses to Active Immunotherapy of Cancer Clin. Cancer Res. 2001;7:1127.

14. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet. 1992;340:1124–7.